Genetics of hepatocellular carcinoma

Seminars in Cancer Biology

Volumn 10, Issue 3, 2000, Pages 185-200

  Annick Buendia, Marie ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

HBV; HCV; Liver cancer; Loss of heterozygosity; Oncogene; Tumor suppressor gene

Indexed keywords

AFLATOXIN B1; AXIN; BETA CATENIN; CADHERIN; EPOXIDE; MANNOSE 6 PHOSPHATE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; ALTERNATIVE RNA SPLICING; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA ADDUCT; DNA BINDING; GENE MAPPING; GENE MUTATION; GENE SILENCING; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HUMAN; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033867475     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0319     Document Type: Article

References (170)

1. Global epidemiology of hepatocellular carcinoma
2. Mortality by cause for eight regions of the world: Global burden of disease study
3. A genetic model for colorectal tumorigenesis
4. The hallmarks of cancer
5. Chromosome abnormalities in peripheral blood cells of hepatitis B virus chronic carriers
6. Cytogenetic findings in three primary hepatocellular carcinomas
7. Chromosome 1p aberrations are frequent in human primary hepatocellular carcinoma
8. Frequent rearrangements of chromosomes 1, 7, and 8 in primary liver cancer
9. Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas
10. Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma
11. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma
12. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma
13. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis
14. Allelotype study of primary hepatocellular carcinoma
15. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas
16. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer
17. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma
18. Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin
19. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma
20. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma
21. Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma
22. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China
23. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas
24. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma
25. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: Loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis
26. Frequent loss of chromosome 8p in hepatitis B virus-positive hepatocellular carcinomas from China
27. Loss of heterozygosity in chromosome 4q12-q13 in hepatocellular carcinoma in Southern African blacks
28. Chromosomal rearrangements and tumor suppressor genes in primary liver cancer
29. Oncogenes, tumor suppressors and co-factors in hepatocellular carcinoma
30. A hypervariable microsatellite revealed by in vitro amplification of a dinucleotide repeat within the cardiac muscle actin gene
31. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction
32. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
33. Comprehensive allelotyping of human hepatocellular carcinoma
34. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas
35. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype
36. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan
37. Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan
38. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization
39. Genetic alterations in hepatocellular carcinomas: Association between loss of chromosome 4q and p53 gene mutations
40. Association of cumulative allelic losses with tumor aggressiveness in hepatocellular carcinoma
41. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma
42. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma
43. Genetic instabilities in human cancers
44. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis
45. Microsatellite instability in European hepatocellular carcinoma
46. Microsatellite instability associated with hepatocarcinogenesis
47. Frequent microsatellite instability in post hepatitis B viral cirrhosis
48. Accumulation of genetic alterations in a human hepatoma cell line transfected with hepatitis B virus
49. Extensive analysis of duplicated-inverted hepatitis B virus integrations in human hepatocellular carcinoma
50. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization
51. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: Their relationship to clinicopathological features
52. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: Relationship to disease stage, tumor size, and cirrhosis
53. The p53 tumor suppressor gene
54. p53, the cellular gatekeeper for growth and division
55. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China
56. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma
57. p53 gene mutation spectrum in hepatocellular carcinoma
58. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation
59. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
60. Mutational hotspot in the p53 gene in human hepatocellular carcinomas
61. p53 mutation in hepatocellular carcinoma after aflatoxin exposure
62. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas
63. Genetic heterogeneity of hepatocellular carcinoma
64. Aflatoxin B1 induces the transversion of G->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes
65. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain
66. Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma
67. Mutations of p53 gene in hepatocellular carcinoma: Roles of hepatitis B virus and aflatoxin contamination in the diet
68. Mutation of p53 gene in hepatocellular carcinoma in Taiwan
69. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis
70. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation
71. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan
72. The presence of HBV genomic DNA in tumor tissue correlates with P53 aberrations in human hepatocellular carcinoma in Qidong, China
73. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: A molecular epidemiological approach
74. p53 mutations in british patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis
75. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence formultistage progression
76. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation
77. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan
78. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China
79. Mutational hotspot in the p53 gene in human hepatocellular carcinomas
80. Aberrations of p53 gene in human hepatocellular carcinoma from China
81. Genetic alterations in hepatocellular carcinomas: Association between loss of chromosome 4q and p53 gene mutations
82. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China
83. The presence of HBV genomic DNA in tumor tissue correlates with P53 aberrations in human hepatocellular carcinoma in Qidong, China
84. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people
85. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese
86. A new mutational hot-spot in the p53 gene in human hepatocellular carcinoma
87. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas
88. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan
89. Mutation of p53 gene in hepatocellular carcinoma in Taiwan
90. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan
91. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas
92. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma
93. p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
94. p53 gene mutation spectrum in hepatocellular carcinoma
95. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation
96. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis
97. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand
98. p53 Mutations in human hepatocellular carcinomas from Germany
99. Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event
100. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation
101. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain
102. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation
103. p53 mutations in british patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis
104. Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma
105. Absence of p53 gene mutations in hepatocarcinomas from a Mediterranean area of Spain. A study of 129 archival tumour samples
106. p53 abnormalities in hepatocellular carcinoma from United States patients: Analysis of all 11 exons
107. Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma
108. p53 is not mutated in hepatocellular carcinomas from Alaska Natives
109. p53 gene in hepatocellular carcinomas from Australia
110. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
111. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal
112. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
113. Identification of the breast cancer susceptibility gene BRCA2
114. Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q
115. RB tumor suppressor gene expression in hepatocellular carcinoma from patients infected with the hepatitis B virus
116. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma
117. Smad2 and Smad4 gene mutations in hepatocellular carcinoma
118. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas
119. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: Identification of three independent regions
120. Mutations in the BRCA2 gene in hepatocellular carcinomas
121. PTEN/MMAC1 mutations in hepatocellular carcinomas: Somatic inactivation of both alleles in tumors
122. Mechanisms and consequences of activation of protein kinase B/Akt
123. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
124. PTEN/MMAC1 mutations in hepatocellular carcinomas
125. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors
126. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
127. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan
128. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level
129. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
130. Deletion mapping of chromosome 16q in hepatocellular carcinoma
131. Morphogenic roles of classic cadherins
132. Cadherins, catenins, and APC protein: Interplay between cytoskeletal complexes and signaling pathways
133. Deletion of the E-cadherin gene in hepatitis B virus-positive Chinese hepatocellular carcinomas
134. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinoma
135. Hypermethylation of tumor suppressor genes in cancer
136. Cancer cell cycles
137. Frequent allelic loss on chromosome 9 in hepatocellular carcinoma
138. High frequency of p16INK4A gene alterations in hepatocellular carcinoma
139. Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma
140. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma
141. Signal transduction of beta-catenin
142. Cadherin-catenin complex: Protein interactions and their implications for cadherin function
143. Association of the APC gene product with b-catenin
144. ̄-catenin is a target for the ubiquitin-proteasome pathway
145. TCF/LEF factor earn their wings
146. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
147. Identification of c-MYC as a target of the APC pathway
148. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer
149. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression
150. Target genes of beta-catenin-T cell factor/lymphoid-enhancer factor signaling in human colorectal carcinomas
151. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors
152. The adenomatous polyposis coli (APC) tumor suppressor
153. Stabilization of beta-catenin by genetic defects in melanoma cell lines
154. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
155. The oncogenic activation of beta-catenin
156. Beta-catenin signaling and cancer
157. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression
158. Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest
159. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas
160. Activation of the beta-catenin gene in primary hepatocellular carcinoma bysomatic alterations involving exon 3
161. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation
162. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas
163. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection
164. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma
165. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity
166. The putative tumor suppressor gene on chromosome 5q for hepatocellular carcinoma is distinct from the MCC and APC genes
167. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis
168. Different frequencies and patterns of beta-catenin mutations in hepatocellular carcinomas induced by N-nitrosodiethylamine and a choline-deficient L-amino acid-defined diet in rats
169. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the b-catenin gene
170. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas